WuXi Biologics, a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that it has received the "CDMO of the Year – Asia Pacific", "Best Biologics CDMO Award: Bioprocessing", and "Best Biologics CDMO in Greater China Region" at the Asia Pacific Biologics CDMO Excellence Awards (APBCEA) 2025 hosted by IMAPAC. Since 2017, WuXi Biologics has received multiple awards in various categories at IMAPAC's events.

APBCEA aims to celebrate the outstanding contributions of leading CDMO that are accelerating biologics innovation across Asia Pacific. This award recognizes excellence in biomanufacturing, cutting-edge R&D, technological innovation, and strategic partnerships that drive the development and commercialization of novel biologic therapies.

Dr. Chris Chen, CEO of WuXi Biologics, commented, "We are very pleased that WuXi Biologics has once again won multiple awards presented by IMAPAC, which fully demonstrates the recognition we have earned from both clients and the industry for the value we consistently deliver. Through unremitting efforts in pursuing excellence, adherence to world-class quality standards, a visionary leadership team, and the dedicated global team, we remain steadfast in empowering our partners to accelerate groundbreaking therapies to patients worldwide at an earlier date."